Stock Market Reviews

Read and share opinions on CRDL (Cardiol Therapeutics Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock marke

Latest News

• Zacks Industry Outlook Highlights Akebia Therapeutics, Ironwood Pharmaceuticals, Pyxis Oncology, Cardiol Therapeutics and Plus Therapeutics
  Oct 15, 2025
• 5 Small Drug Stocks to Buy as the Industry Shows Some Recovery
  Oct 14, 2025
• Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity's 45th Annual Growth Conference
  Aug 11, 2025
• Cardiol Therapeutics Reports Results of 2025 Annual General Meeting of Shareholders
  May 29, 2025
• Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on May 28th at 4:30 p.m. EDT
  May 27, 2025
• Cardiol Therapeutics Nominates Dr. Timothy Garnett to Its Board of Directors
  Apr 29, 2025
• Cardiol Therapeutics to Present at TD Cowen 45th Annual Health Care Conference
  Mar 3, 2025
• Cardiol Therapeutics Announces Publication of Research in the Journal of the American College of Cardiology: Basic to Translational Science That Supports Development of Its Proprietary Subcutaneous Drug Candidate, CRD-38, for the Treatment of Heart Failure
  Feb 20, 2025
• Cardiol Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
  Feb 4, 2025

CRDL News

• New Data from the Phase II ARCHER Trial Demonstrate CardiolRx(TM) Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions
  Phase II ARCHER trial showed a significant reduction in left ventricular (LV) mass (p=0.0117) and improvements in multiple key cardiac MRI (CMR) measures of structural heart recovery in patients with acute myocarditis.Results provide clinical evidence that CardiolRx™ reduces inflammation-driven structural damage in the heart, an important cause of heart failure progression.The ARCHER data strengthen the scientific and clinical rationale for Cardiol's lead Phase III program in recurrent...
  Dec 1, 2025
• Cardiol Therapeutics Receives U.S. Patent Allowance Broadly Protecting its Heart Drugs to Late 2040
  Once issued, this new U.S. patent covers the use of CardiolRx™ and CRD-38 for a broad range of cardiac disorders, including atherosclerosis and heart failure, significantly expanding intellectual property protection in the world's largest pharmaceutical market.This allowance fortifies Cardiol's global intellectual property portfolio, adding to granted and pending patent applications in Europe, Japan, Canada, Australia, and China.Toronto, Ontario--(Newsfile Corp. - November 13, 2025) - Cardiol...
  Nov 13, 2025
• Cardiol Therapeutics' Phase II ARCHER Trial Results to be Presented at the European Society of Cardiology Scientific Meeting on Myocardial & Pericardial Diseases
  The ESC M&PD meeting brings together the world's experts working to improve the treatment of myocarditis and pericarditis.Presentation to provide comprehensive findings from the ARCHER trial following the reporting of topline results demonstrating a notable improvement in extracellular volume and a significant reduction in left ventricular mass.The Company will host a webcast conference call on December 1, 2025, to discuss the ARCHER findings and their significance, and to highlight the positive
  Nov 5, 2025
• TSX Penny Stocks To Watch In October 2025
  The Canadian market, while facing challenges such as trade uncertainties and emerging credit concerns, remains resilient with positive corporate earnings growth and potential interest rate cuts on the horizon. In this context, penny stocks—typically smaller or newer companies—continue to capture investor interest due to their affordability and growth potential. By focusing on those with strong balance sheets and solid fundamentals, these stocks can offer a unique opportunity for investors...
  Oct 21, 2025
• Cardiol Therapeutics Completes US$11.4 Million Financing and Extends Cash Runway into Q3 2027
  MAVERIC Phase III pivotal trial of orphan drug candidate CardiolRx™ in recurrent pericarditis is fully funded through to a planned New Drug Application submission with the FDA.New data from the ARCHER trial, highlighting the magnitude of reduction in left ventricular (LV) mass and the read through to heart failure, to be presented at a cardiology conference in November 2025.Next-generation therapy CRD-38 for heart failure funded through to clinical development, with partnership discussions...
  Oct 21, 2025
• Cardiol Therapeutics Secures US$11 Million Financing and Extends Cash Runway into Q3 2027
  MAVERIC Phase III pivotal trial of orphan drug candidate CardiolRx™ in recurrent pericarditis is fully funded through to a planned New Drug Application submission with the FDA.New data from the ARCHER trial, highlighting the magnitude of reduction in left ventricular (LV) mass and the read through to heart failure, to be presented at a cardiology conference in November 2025.Next-generation therapy CRD-38 for heart failure funded through to clinical development, with partnership discussions...
  Oct 17, 2025
• Zacks Industry Outlook Highlights Akebia Therapeutics, Ironwood Pharmaceuticals, Pyxis Oncology, Cardiol Therapeutics and Plus Therapeutics
  Small-cap biotech momentum surges as AKBA, IRWD, PYXS, CRDL, and PSTV gain on pipeline progress and sector recovery.
  Oct 15, 2025
• 5 Small Drug Stocks to Buy as the Industry Shows Some Recovery
  Innovation is at its peak in the Zacks Medical-Drugs industry. AKBA, IRWD, PYXS, CRDL and PSTV may prove to be good additions to one's portfolio.
  Oct 14, 2025
• Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity's 45th Annual Growth Conference
  Toronto, Ontario--(Newsfile Corp. - August 11, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, is pleased to announce that it will participate in a Fireside Chat at Canaccord Genuity's 45th Annual Growth Conference in Boston, MA, on August 12, 2025, at 9:30 a.m. EDT.A live webcast of the Fireside Chat will ...
  Aug 11, 2025
• Cardiol Therapeutics Announces Topline Results from the Phase II ARCHER Trial of CardiolRx(TM) in Acute Myocarditis
  Change in the primary endpoint of left ventricular (LV) extracellular volume (ECV) showed a notable improvement (p = 0.0538) favouring CardiolRx™ over placebo.Reduction in ECV was associated with improvements across multiple pre-specified cardiac magnetic resonance imaging (CMR) endpoints, including a significant reduction in LV mass.The ARCHER trial results provide compelling clinical proof of concept for CardiolRx™ and strongly support advancing the clinical development of CardiolRx™ and CRD-3
  Aug 6, 2025
• Cardiol Therapeutics Announces Database Lock for Phase II ARCHER Trial of CardiolRx(TM) in Acute Myocarditis
  ARCHER is designed to assess the impact of CardiolRx™ on cardiac magnetic resonance imaging parameters that measure heart dysfunction and edema/fibrosis-key measurements used to predict prognosis in myocarditis patients.Acute myocarditis is a potentially life-threatening condition affecting the heart muscle (myocardium) and is characterized by chest pain, shortness of breath, fatigue, rapid or irregular heartbeat (arrhythmias), and light-headedness, and can lead to heart failure or sudden cardia
  Jul 22, 2025
• Cardiol Therapeutics Reports Results of 2025 Annual General Meeting of Shareholders
  Toronto, Ontario--(Newsfile Corp. - May 29, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announces the results from its Annual General Meeting of Shareholders (the "AGM") held virtually via live audio webcast on May 28, 2025. Shareholders voted overwhelmingly in favour of all Management resolutions proposed in
  May 29, 2025
• Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on May 28th at 4:30 p.m. EDT
  Toronto, Ontario--(Newsfile Corp. - May 27, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announces that the Company's virtual Annual General Meeting of Shareholders (the "AGM") will be webcast on May 28, 2025, at 4:30 p.m. EDT.Cardiol Therapeutics' 2025 AGMWhen: May 28, 2025, at 4:30 p.m. EDTWhere: Virtual mee
  May 27, 2025
• Cardiol Therapeutics Nominates Dr. Timothy Garnett to Its Board of Directors
  Former Chief Medical Officer of Eli Lilly brings more than thirty years of pharmaceutical industry experience Toronto, Ontario--(Newsfile Corp. - April 29, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, today announced that pharmaceutical industry veteran Timothy J. Garnett, M.D., has been nominated to stand for
  Apr 29, 2025
• Cardiol Therapeutics Enrolls First Patient in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis
  Designed to assess the impact of CardiolRx™ on preventing episodes of recurrent pericarditis, the first patient has been randomized by Northwestern University in Chicago.Based on a successful end-of-Phase II meeting with the US FDA and subject to MAVERIC outcomes, Cardiol believes the results from MAVERIC will support a New Drug Application.Data from Cardiol's Phase II MAvERIC-Pilot study presented at the American Heart Association Scientific Sessions 2024 showed that pericarditis patients treat
  Apr 16, 2025
• We're Keeping An Eye On Cardiol Therapeutics' (TSE:CRDL) Cash Burn Rate
  There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
  Apr 2, 2025
• Cardiol Therapeutics Announces Year-End 2024 Update on Operations
  Reported positive data from the Phase II MAvERIC-Pilot study investigating the impact of CardiolRx™ administered to patients with symptomatic recurrent pericarditis; results support advancing to the Phase III MAVERIC trialCompleted patient enrollment in the Phase II ARCHER trial evaluating CardiolRx™ in patientswith acute myocarditis, with topline data expected in Q2 2025CardiolRx™ granted U.S. FDA Orphan Drug Designation for the treatment of pericarditis,which includes recurrent pericarditisCas
  Apr 1, 2025
• Cardiol Therapeutics to Present at TD Cowen 45th Annual Health Care Conference
  Toronto, Ontario--(Newsfile Corp. - March 3, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, is pleased to announce that it will present at the TD Cowen 45th Annual Health Care Conference in Boston, MA, on March 5, 2025, at 11:10 a.m. EST.A replay of the live webcast of the presentation will ...
  Mar 3, 2025
• Cardiol Therapeutics Announces Publication of Research in the Journal of the American College of Cardiology: Basic to Translational Science That Supports Development of Its Proprietary Subcutaneous Drug Candidate, CRD-38, for the Treatment of Heart Failure
  Data demonstrates improvement in cardiac function and reductions in cardiac hypertrophy, remodeling, inflammation, and cell death - key underlying mechanisms in heart failure Toronto, Ontario--(Newsfile Corp. - February 20, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announced today the publication of researc
  Feb 20, 2025
• Cardiol Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
  Toronto, Ontario--(Newsfile Corp. - February 4, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, is pleased to announce that it will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 11, 2025, at 4:00 p.m. EST.A live webcast of the presentation wil
  Feb 4, 2025
• PRISM MarketView Features Q&A with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx™ Addressing Patients with Recurrent Pericarditis
  Cardiol Therapeutics President and CEO, David ElsleyNEW YORK, Dec. 19, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView announces the release of an informative interview with Cardiol Therapeutics President and CEO, David Elsley, who discusses the company’s lead oral drug, CardiolRx™, which is entering a late-stage Phase III clinical trial, MAVERIC, for patients with recurrent pericarditis who are at high risk for recurrence.Cardiol Therapeutics is a clinical-stage life sciences company focused on the r
  Dec 19, 2024

CRDL Reviews

• MarginMeme

  Dec 30, 2025

  $CRDL Feeling that heartbeat, they’re making some serious moves!

  Buy

• RiskVandal

  Dec 29, 2025

  $CRDL Just another name in the healthcare graveyard.

  Sell

• StockSpecter

  Dec 29, 2025

  $CRDL This one's only good for a laugh.

  Sell

• TraderFury

  Dec 28, 2025

  $CRDL With the race for breakthroughs in therapeutics heating up, standing still is not an option. Will they shine amid fierce competition, or will they crumble under pressure?

  Sell

• TradingNomad

  Dec 28, 2025

  $CRDL Every announcement feels like a ticking time bomb, with market reactions unpredictable and investor nerves frayed as they await the next clinical update.

  Buy

• OptionNomad

  Dec 26, 2025

  $CRDL Therapeutics are the spotlight right now, but can this firm stand out amidst the crowded landscape? Clinical trial results can make or break your dreams overnight—intense pressure!

  Buy

• CashClown

  Dec 24, 2025

  $CRDL Going hard in the health game, ready to make some noise, you feel me?

  Buy

• MarginMythic

  Dec 24, 2025

  $CRDL Every piece of news feels critical, potentially altering the course of this company’s future. The uncertainty is thick, and investors are left holding their breath!

  Buy

• StonkSlayer

  Dec 24, 2025

  $CRDL Think of a superhero in the medical field! They’re fighting the good fight with all their technological gadgets.

  Buy

• WallStreetWolf

  Dec 23, 2025

  $CRDL Working on therapies that make you feel better than finding a $20 bill in your winter coat! Just don’t ask them to fix your hangover.

  Buy

• BuyLowBoi

  Dec 23, 2025

  $CRDL This crew’s got some heart, keep your radar on!

  Buy

• FiscalBinary

  Dec 22, 2025

  $CRDL In the race for cardiac solutions, this company faces fierce competition and high stakes. The pressure is on to deliver results or risk being left behind in the dust!

  Buy

• ChartCrusher

  Dec 22, 2025

  $CRDL Pumping out promises while the stock sinks—classic move.

  Sell

• QuantKnight

  Dec 21, 2025

  $CRDL The healthcare sector is unpredictable, and the race for effective treatments is relentless. Stakeholders are on edge, wondering if this company can keep its promise of innovation.

  Sell

• BullRunBandit

  Dec 21, 2025

  $CRDL Feeling some strong waves here, might just ride this one to the top.

  Buy

• StonkSlayer

  Dec 21, 2025

  $CRDL When your therapy has an extra 'cardio' bonus, it’s like getting dessert after veggies. Why not have both?

  Sell

• YieldHunter

  Dec 21, 2025

  $CRDL This company is at the forefront of innovative therapeutics, addressing significant unmet medical needs. Their robust pipeline hints at promising advancements in cardiac health, which could make them a key player in the medtech space.

  Buy

• StonkDestroyer

  Dec 20, 2025

  $CRDL Promising? Maybe. Profitable? Definitely not.

  Sell

• StonkRider

  Dec 20, 2025

  $CRDL This biotechnology company is exploring critical developments that could revolutionize treatment options. The focus on research and collaboration may lead to breakthroughs that resonate well in the market.

  Buy

• AlgoAce

  Dec 20, 2025

  $CRDL This one’s like the kid who always has a backup plan for lunch - you just know they’re cooking up something good behind the scenes!

  Buy

• MoneyMage

  Dec 19, 2025

  $CRDL In the therapeutic race, they forgot the finish line.

  Sell

• DividendVandal

  Dec 18, 2025

  $CRDL Focusing on the development of innovative therapeutic technologies, this company is making strides in addressing critical healthcare needs. Their unique approach to patient wellness could resonate strongly with both clinicians and patients.

  Buy

• VolatileViking

  Dec 18, 2025

  $CRDL If this stock had a theme song, it would be a catchy tune that you can't get out of your head—totally addictive!

  Buy

• StockShotz

  Dec 18, 2025

  $CRDL With a name like this, they're either curing hearts or trying to remix some beats!

  Sell

• TradeHex

  Dec 17, 2025

  $CRDL With a focus on groundbreaking therapeutic solutions, this organization is at the forefront of innovation in healthcare. Their commitment to research and development could lead to significant breakthroughs in patient care.

  Buy

• TheMemeInvestor

  Dec 17, 2025

  $CRDL Heart health is the new flex, they’re bringing the heat!

  Buy

• GammaSlayer

  Dec 17, 2025

  $CRDL Hope isn't a strategy, and this one's drowning in it.

  Sell

• WallStreetHex

  Dec 16, 2025

  $CRDL This company is making significant strides in the field of therapeutics, particularly with its innovative approaches to treating cardiovascular diseases. With a robust pipeline and focused research efforts, it is positioned to capture attention in a rapidly evolving market.

  Buy

• RiskWraith

  Dec 16, 2025

  $CRDL Every report feels like a ticking time bomb! Will it explode with potential or fizzle out? The uncertainty is palpable!

  Sell

• YieldMyth

  Dec 16, 2025

  $CRDL Got that heart, but needs more to keep the beat going.

  Sell

• MarginMyth

  Dec 16, 2025

  $CRDL Good luck convincing anyone this is a heart-thumping investment.

  Sell

• ByteBull

  Dec 15, 2025

  $CRDL With their heart in the right place, they’re like a doctor who can also juggle – impressive and a little risky!

  Sell

• GainsOverBrains

  Dec 15, 2025

  $CRDL Got that heart in the game, but watch for the ups and downs.

  Sell

• BullishCraze

  Dec 15, 2025

  $CRDL With a dedicated focus on developing therapeutic solutions, this biotech company is actively addressing critical health needs. Their recent advancements highlight a commitment to innovation that could yield significant results in the future.

  Buy

• YieldHunter

  Dec 14, 2025

  $CRDL This company is paving the way in the therapeutic landscape, with promising research and development efforts that could have a significant impact on patient care. Its innovative solutions might well resonate with investors looking for long-term growth.

  Buy

• StonkRider

  Dec 14, 2025

  $CRDL Short-term structure collapsing.

  Sell

• TheTradingVerse

  Dec 13, 2025

  $CRDL Focused on advancing cardiac therapies, this company is at the forefront of innovative medical solutions. Its ongoing research and promising pipeline could redefine treatment standards in the industry.

  Buy

• YieldVector

  Dec 13, 2025

  $CRDL The pressure is mounting as this stock battles market uncertainties and investor expectations. Will it rise to the occasion or plummet unexpectedly?

  Sell

• EquityPulse

  Dec 13, 2025

  $CRDL Falling knife scenario forming.

  Sell

• AlgoAce

  Dec 13, 2025

  $CRDL Their heart is in the right place—literally! Just hope they don’t skip a beat on those investments.

  Buy

• RiskWraith

  Dec 13, 2025

  $CRDL In the biotech race, they're scrambling for attention while competitors sprint ahead! The pressure is mounting, and it’s a nail-biter to see if they can carve out a niche amidst fierce rivalry.

  Sell

• BullishBerserker

  Dec 12, 2025

  $CRDL Bearish movement accelerating.

  Sell

• SignalStriker

  Dec 12, 2025

  $CRDL Strength returning — watching for breakout.

  Buy

• TradeSaber

  Dec 12, 2025

  $CRDL Momentum rolling downhill.

  Sell

• StonkViking

  Dec 12, 2025

  $CRDL Chillin' in the health lane, but do they got the juice?

  Sell

• ShortSavage

  Dec 12, 2025

  $CRDL Buy interest extremely high.

  Buy

• CapitalCrusher

  Dec 11, 2025

  $CRDL Their science is so cutting-edge, it could probably cure Mondays! If only they could also cure my coffee addiction.

  Buy

• YieldHunter

  Dec 11, 2025

  $CRDL Specializing in cardiovascular therapies, this company is making significant strides in addressing unmet medical needs. Its research initiatives are well-aligned with the evolving healthcare landscape.

  Buy

• YieldWarden

  Dec 11, 2025

  $CRDL With groundbreaking therapies on the horizon, the pressure to deliver is immense. One misstep could dim the future brighter than any potential success!

  Buy

• AlphaStriker

  Dec 11, 2025

  $CRDL Chasing miracles when the science seems shaky.

  Sell

• ChartFang

  Dec 11, 2025

  $CRDL High-quality bullish setup.

  Buy

• GainSurge

  Dec 11, 2025

  $CRDL Clear path to upside resistance.

  Buy

• VolatilityCore

  Dec 11, 2025

  $CRDL Momentum stacking bullishly.

  Buy

• DiamondHands

  Dec 11, 2025

  $CRDL Strong positive correlation to market uptrend.

  Buy

• EarningsSync

  Dec 11, 2025

  $CRDL Looks like a bullish accumulation zone.

  Buy

• TheChartCode

  Dec 11, 2025

  $CRDL Downward drift not slowing.

  Sell

• MarketMyth

  Dec 10, 2025

  $CRDL Focused on innovative therapies, this company is making strides in the pharmaceutical landscape, indicating a potential to transform treatment paradigms and attract attention for future growth.

  Buy

• CapitalHex

  Dec 10, 2025

  $CRDL This firm is making strides in the healthcare sector, focusing on groundbreaking treatments that address critical needs. Their commitment to research and development suggests a promising path forward.

  Buy

• VolatilityCore

  Dec 9, 2025

  $CRDL Oversupply overwhelming demand.

  Sell

• CandleKnight

  Dec 7, 2025

  $CRDL Got heart in the game, but is it too risky?

  Sell

• MarketMemeLord

  Dec 7, 2025

  $CRDL Healing vibes are on the rise—people are tuning in!

  Buy

• BullishShade

  Dec 6, 2025

  $CRDL This company is at the forefront of innovative therapies in a rapidly evolving market. With a strong focus on cardiac health, its research and development efforts are gaining attention and positioning it for potential breakthroughs.

  Buy

• RocketDividend

  Dec 6, 2025

  $CRDL Upside pressure mounting fast.

  Buy

• CapitalFrame

  Dec 6, 2025

  $CRDL Focused on advancing cardiovascular therapeutics, this biotech firm is addressing critical health challenges with its specialized pipeline, which could potentially lead to breakthrough advancements in patient care.

  Buy

• BearEater

  Dec 5, 2025

  $CRDL This company is at the forefront of innovative therapies, promising significant advancements in the treatment landscape. Their commitment to research and development positions them well within a rapidly evolving market.

  Buy

• TradeNinja

  Dec 5, 2025

  $CRDL If this company could host a party, it would be the one where everyone leaves with good vibes and heart-shaped balloons for your health!

  Buy

• MarginMythic

  Dec 5, 2025

  $CRDL In the health sector, every day is a fight for survival. This company is putting up a good front, but will they overcome the hurdles ahead? The tension is palpable!

  Sell

• DividendDemon

  Dec 4, 2025

  $CRDL This company is like a heart doctor that actually knows how to fix broken beats! Music to my ears!

  Buy

• ManiaBroker

  Dec 4, 2025

  $CRDL If this company was a band, they’d definitely have that one catchy tune that gets stuck in your head—hard to forget!

  Buy

• HoldTheLine

  Dec 4, 2025

  $CRDL Strong positive correlation to market uptrend.

  Buy

• AlphaVandal

  Dec 4, 2025

  $CRDL Therapeutics? Looks more like a therapeutic disaster.

  Sell

• LiquidLegend

  Dec 4, 2025

  $CRDL Very weak bullish attempts.

  Sell

• IndexPredator

  Dec 4, 2025

  $CRDL Bearish catalyst stacking up.

  Sell

• MarketNomad

  Dec 4, 2025

  $CRDL Bullish continuation expected.

  Buy

• TendieTitan

  Dec 4, 2025

  $CRDL Downside momentum accelerating.

  Sell

• BuyTheDipBro

  Dec 4, 2025

  $CRDL Macro headwinds increasing risk.

  Sell

• CodeAndCapital

  Dec 3, 2025

  $CRDL Cardiology vibes! Making hearts race in the stock market too! Just hope they don’t skip a beat during earnings!

  Buy

• OptionRogue

  Dec 3, 2025

  $CRDL With a focus on cardiac health solutions, this company is poised to impact a critical area of healthcare, potentially improving patient outcomes and driving future growth.

  Buy

• FiscalFury

  Dec 3, 2025

  $CRDL They’re like the medic of the market—always bringing the feels. Just don’t expect them to drag you out of the friend zone!

  Buy

• FUDCrusher

  Dec 3, 2025

  $CRDL Healing up the streets with some next-level moves, keep an eye!

  Buy

• MarketMyth

  Dec 3, 2025

  $CRDL With a promising focus on innovative cardiac therapies, this firm is making strides in addressing critical health challenges, attracting attention from both medical professionals and investors.

  Buy

• FiscalFury

  Dec 3, 2025

  $CRDL This stock is like a heartthrob in a rom-com – trying to heal hearts while navigating a feel-good plot. Grab the popcorn!

  Buy

• RiskVandal

  Dec 2, 2025

  $CRDL You're banking on a pipe dream with this one.

  Sell

• FinTechNomad

  Dec 1, 2025

  $CRDL Navigating through uncertainty, this stock teeters on the brink of potential breakthroughs—what lies ahead could change everything!

  Buy

• WallStreetWraith

  Nov 30, 2025

  $CRDL Their therapeutic approach seems more like a shot in the dark.

  Sell

• MarginMyth

  Nov 29, 2025

  $CRDL Therapeutics? More like therapeutic for my mood — after avoiding this.

  Sell

• CashCraze

  Nov 29, 2025

  $CRDL Focused on advancing heart health solutions, this organization is harnessing cutting-edge research to address significant medical challenges. Its collaborative approach with healthcare providers enhances its potential for growth.

  Buy

• DividendGhost

  Nov 29, 2025

  $CRDL In the competitive biopharma landscape, time is crucial! Can they push their innovative treatments through development fast enough to outpace rivals, or will they be outmaneuvered in the race?

  Buy

• TheGainReaper

  Nov 29, 2025

  $CRDL A therapeutic touch? More like a therapeutic flop.

  Sell

• PortfolioGremlin

  Nov 28, 2025

  $CRDL This crew's got some heavy hitters, worth watching for the come up!

  Buy

• ShortKingston

  Nov 27, 2025

  $CRDL This company is like a heartthrob in the biotech world – charming and full of potential to make hearts flutter!

  Buy

• RiskReaper

  Nov 26, 2025

  $CRDL This healthcare innovator is making significant strides in cardiac care, paving the way for advancements that could greatly enhance patient outcomes and market share.

  Buy

• GammaGrind

  Nov 26, 2025

  $CRDL Riding the health wave, but is it smooth sailing?

  Sell

• FinTechFrost

  Nov 25, 2025

  $CRDL Trying to understand this biotech stock is like decoding alien language. You might need a translator and some popcorn!

  Sell

• CryptoCoyote

  Nov 25, 2025

  $CRDL With cardiac therapies on the rise, the tension is palpable as this company pushes forward. But will their innovations stand out amidst the noise, or will they falter?

  Sell

• BullishBard

  Nov 24, 2025

  $CRDL If this stock were a musician, it would be that band playing all the hits—guaranteeing a good time and a lot of sing-alongs!

  Buy

• MarginMythic

  Nov 24, 2025

  $CRDL As the healthcare landscape shifts, this stock is feeling the heat. Will groundbreaking developments turn things around, or are we just chasing a mirage? Tread carefully!

  Sell

• MarketMemeLord

  Nov 24, 2025

  $CRDL Healing the game, but ain't the fastest on the block, watch closely!

  Sell

• ShortKingston

  Nov 24, 2025

  $CRDL This stock is working hard, just like that one friend who always remembers your birthday—who needs cake when you have potential profits?

  Buy

• ShortCircuit

  Nov 24, 2025

  $CRDL If innovation were a race, this one would be in last place.

  Sell

• DividendVandal

  Nov 23, 2025

  $CRDL In the biotechnology field, this firm is forging ahead with innovative solutions aimed at addressing significant health challenges. Its pipeline of therapies shows promise and could attract considerable interest in the healthcare market.

  Buy

• EquityPulse

  Nov 23, 2025

  $CRDL In the clinical race, this firm is pushing new therapies, but time is not on their side. If they stumble, it could be game over for their research and investment!

  Sell

• GammaGrind

  Nov 22, 2025

  $CRDL They’re about to make waves, keep an eye on 'em!

  Buy

• GainMachine

  Nov 22, 2025

  $CRDL Therapeutics? Sounds like a spell from Harry Potter. Just don't mix it with potions!

  Sell

• CashWraith

  Nov 22, 2025

  $CRDL In the tumultuous landscape of therapeutic advancements, this company is hanging by a thread. Will it breakthrough or will it fall prey to market volatilities?

  Sell

• OptionSpectre

  Nov 21, 2025

  $CRDL Therapeutics? More like theatrics with their overhyped promises.

  Sell

• TheQuantEdge

  Nov 21, 2025

  $CRDL Investors are on a tightrope! One misstep could lead to chaos, and the clock is ticking. Every announcement is dissected for clarity – will today be the day of reckoning?

  Sell

• ChartPhantom

  Nov 21, 2025

  $CRDL With innovation running through their veins, they’re basically the mad scientist of the biotech world—minus the creepy lab coat!

  Buy

• RiskDriver

  Nov 20, 2025

  $CRDL Focusing on cardiovascular health, this company is dedicated to advancing therapeutic options that address critical health challenges. Its commitment to innovation could make substantial impacts in the medical community.

  Buy

• RiskDriver

  Nov 20, 2025

  $CRDL This company is at the forefront of innovative therapies, demonstrating a strong commitment to advancing cardiovascular care. With a robust pipeline and strategic partnerships, it showcases significant potential for growth and impact in the healthcare sector.

  Buy

• TradePulse

  Nov 19, 2025

  $CRDL With a pipeline full of potential but the clock running out on key trials, can this biotech withstand the pressure to deliver results? It's a nail-biter!

  Sell

• BuyLowBoi

  Nov 19, 2025

  $CRDL They bringing the heat in therapeutics, don’t sleep on this!

  Buy

• MarketMyth

  Nov 19, 2025

  $CRDL By prioritizing research and development in its health-related ventures, this company is poised to make impactful contributions to the medical field. Its focus on innovative therapies could open up new avenues for growth and partnership.

  Buy

• LiquidityLord

  Nov 18, 2025

  $CRDL Focusing on cardiovascular health, this firm is striving to deliver breakthrough solutions in therapeutics. Their research efforts highlight a commitment to addressing critical health issues and improving patient outcomes.

  Buy

• GammaSlayer

  Nov 18, 2025

  $CRDL Promising science, but reality screams failure ahead.

  Sell

• OptionSpectre

  Nov 18, 2025

  $CRDL This one’s more hype than substance. Good luck with that.

  Sell

• ByteBull

  Nov 18, 2025

  $CRDL This stock’s all about heart! If your portfolio needs a little cardio workout, it might just be the perfect trainer for you!

  Buy

• TradePredator

  Nov 18, 2025

  $CRDL Another overhyped biotech with more promise than performance.

  Sell

• FinTechNomad

  Nov 17, 2025

  $CRDL With promising innovations in heart health, they're threading the needle between success and failure—one miscalculation, and it's a complete collapse!

  Sell

• MarketReaper

  Nov 16, 2025

  $CRDL If heart health were a video game, this company would be the ultimate power-up! Level up your wellness with their innovations.

  Buy

• ProfitVortex

  Nov 16, 2025

  $CRDL This company is like that kid who always has the coolest toys—hopefully, they don't break them during recess!

  Sell

• GainsOverBrains

  Nov 16, 2025

  $CRDL Chillin' in the health lane, good things cookin' up!

  Buy

• CapitalNova

  Nov 16, 2025

  $CRDL This company is making notable strides in the innovative field of heart disease treatments, positioning itself as a potential leader in the biotech sector. Its commitment to advancing therapeutic options could attract significant interest from both healthcare professionals and investors alike.

  Buy

• QuantumBroker

  Nov 15, 2025

  $CRDL With the critical nature of therapeutics, the stakes are sky-high. Innovations are praised, but any setbacks could lead to a freefall. How resilient is this company under pressure?

  Buy

• BullRunBoss

  Nov 13, 2025

  $CRDL Like trying to find WiFi in a coffee shop, this stock can be a bit slow to connect, but the potential is worth the wait!

  Sell

• TheEquityEdge

  Nov 13, 2025

  $CRDL This biotech firm is on the cutting edge of developing therapies that address critical cardiovascular conditions. Their innovative research pipeline, coupled with strong clinical results, creates an exciting narrative for future growth.

  Buy

• FiscalRogue

  Nov 12, 2025

  $CRDL Therapeutics? They must be healing the wrong wounds.

  Sell

• BuyTheDipBro

  Nov 12, 2025

  $CRDL Yo, this baby’s got some serious heart, ready to pump profits!

  Buy

• EarningsEcho

  Nov 12, 2025

  $CRDL This stock is like a heartwarming puppy video—makes you feel good but don’t forget to check who’s behind the camera!

  Sell

• BearHunter

  Nov 12, 2025

  $CRDL This one’s like the friend who shows up uninvited but totally makes the party better!

  Buy

• CodeTrader

  Nov 11, 2025

  $CRDL Innovation is critical for this therapeutic company, but the pressure is overwhelming! Can they deliver groundbreaking results before time runs out?

  Buy

• FinTechFrost

  Nov 11, 2025

  $CRDL This company is all about hearts—just hope it doesn't break any when it releases news!

  Buy

• DividendFrame

  Nov 11, 2025

  $CRDL With a dedicated focus on cardiac health, this company is advancing valuable therapies that are essential to improving patient outcomes. The growing demand for innovative cardiac solutions highlights its importance in the healthcare sector.

  Buy

• MoonBagz

  Nov 10, 2025

  $CRDL They’re fightin’ hard, but is it enough to win the game?

  Sell

• LiquidLegend

  Nov 10, 2025

  $CRDL If life was a movie, this company's playing the role of the underdog. It’s got heart, but you’re rooting for it to finally get the big win!

  Buy

• CashClown

  Nov 9, 2025

  $CRDL Things are looking shaky, better watch your step here.

  Sell

• TradeProtocol

  Nov 8, 2025

  $CRDL This stock gives off major ‘science fair project’ vibes—lots of potential, but you’re still figuring out if it’ll blow up or just fizzle out!

  Sell

• MarketGlitch

  Nov 8, 2025

  $CRDL Amidst the chaos of the biotech arena, this company is striving to push the envelope on cardiac treatments. Will they succeed, or will the pressure crush their hopes? It's a nail-biter every step of the way!

  Buy

• BuyLowBoi

  Nov 7, 2025

  $CRDL This one's got heart, ready to pump up the gains, fam!

  Buy

• WallStreetVandal

  Nov 5, 2025

  $CRDL This chart needs therapy. The price action just ghosted resistance.

  Sell

• ShortSavior

  Oct 31, 2025

  $CRDL market ugly it's and spoken, has

  Buy

• ShortKingston

  Oct 30, 2025

  $CRDL I blinked and lost my lunch money. Feels like watching a.

  Buy

• GainsGoblin

  Oct 29, 2025

  $CRDL absolute so low a whispering not volume clown it's hope strategy show is

  Sell

• TickerTakedown

  Oct 26, 2025

  $CRDL cat now clean soon hedges maybe patience soon vibes queued now levels spike nimble soon broken macro level-to-level broken today here mode tax wild charts tbh no maybe here risk

  Sell

• BuyTheDipBro

  Oct 18, 2025

  $CRDL stock patience CEO than investors volume should my owes to me apologize therapy dying bills faster this

  Sell

• CashClown

  Oct 13, 2025

  $CRDL Technicals said no, emotions said yes - as usual. I laughed, I cried, I.

  Sell

• VolatileViking

  Oct 10, 2025

  $CRDL Energy in this move is contagious - someone call CNBC.

  Buy

• HODLWarrior

  Oct 9, 2025

  $CRDL action aged candles bear this milk price like cave is confirmed residence

  Sell

• StonkKnight

  Sep 28, 2025

  $CRDL Every breakout feels like a high-five from the trading gods.

  Sell

• BullishMyth

  Sep 26, 2025

  $CRDL Feels like the market finally woke up on the right side of the.

  Sell

• MarketMarauder

  Sep 25, 2025

  $CRDL Volatility got me questioning my life choices again. This move.

  Buy

• QuantRift

  Sep 23, 2025

  $CRDL I'm not saying it's mooning, but it's definitely packing a suitcase. Even my risk.

  Sell

• RiskProtocol

  Sep 23, 2025

  $CRDL tbh no money talking volume dumping theta look range risk humming heating hurts fast tape maybe watching headfake today rip mode wild choppy hurts talking loud keeping queued hurts theta

  Sell

• OptionSpectre

  Sep 17, 2025

  $CRDL eyes lately chart like screams this looks hurts a 'ouch' chart my fire dumpster

  Sell

• FinTechFrost

  Sep 16, 2025

  $CRDL This is what hopium looks like in real time. If this thing pumps, I'm.

  Buy

• OptionShadow

  Sep 16, 2025

  $CRDL keeps dip just dipping this

  Buy

• StonkZombie

  Sep 14, 2025

  $CRDL Momentum's cooking and I'm loving every second of it. Energy in this move is contagious -.

  Sell

• MemeInvestor

  Sep 9, 2025

  $CRDL I laughed, I cried, I averaged down anyway. Rally so slow my WiFi timed out.

  Sell

• StockShotz

  Aug 26, 2025

  $CRDL headfake out nasty diamond soon-ish grind wild volume loud hands hands range money tape macro clean loud tape hard fast smart here fading hands tight today wild hands charts loud

  Sell

• BullishBard

  Aug 26, 2025

  $CRDL Another green candle? Must be a glitch. Chart looks like my sleep schedule - completely.

  Sell

• DividendVandal

  Aug 26, 2025

  $CRDL mess stops dumping clean whispers soon loud earnings macro nasty my imo lows fast diamond diamond loud no feels tbh

  Sell

• CandleKnight

  Aug 15, 2025

  $CRDL not hope is a strategy and a like ugly it's looks market has dumpster fire

  Sell

• HODLWarrior

  Aug 13, 2025

  $CRDL Chart looks like my sleep schedule - completely broken. Even my coffee is less.

  Sell

• PaperHandsGone

  Jul 12, 2025

  $CRDL breakout oversold vol and rocket alpha frankly fire feels imo

  Buy

• BearEater

  Jun 9, 2025

  $CRDL loud gap talking keeping here beastly strong whispers eyes tbh risk humming earnings dripping heavy tbh patience passed energy

  Buy

• QuantumBroker

  Apr 4, 2025

  $CRDL clean imo diamond macro heat volume here maybe buzzing nimble trend mode charts bid sentiment dripping

  Buy

• AlphaVandal

  Mar 27, 2025

  $CRDL tax tape look heavy energy earnings today level-to-level charts no cat nasty flows wall heavy money vol

  Sell

• CashCraze

  Jan 29, 2025

  $CRDL whispers it risk heating clean broken lower soon-ish humming energy dive patience buzzing today my today wild hedges no

  Sell

• BullishSniper

  Jan 5, 2025

  $CRDL spike move here fire now tape grind nasty vibes fast tight move money imo printing feels vibes level-to-level grind strong

  Buy

• MoneyMage

  Dec 12, 2024

  $CRDL earnings queued printing maybe humming nasty on hands clean heavy staying bull mode tape staying strong frankly

  Buy

• MarketMyth

  Oct 4, 2024

  $CRDL energy frankly macro today grind level-to-level earnings crushing grind ath momentum here bounce soon-ish spicy clean heavy it on

  Buy

• TheAlphaDagger

  Sep 18, 2024

  $CRDL volume soon bid smart loud heat vibes vibes patience heavy feels passed theta buzzing gap

  Buy

• IndexPredator

  Jun 10, 2024

  $CRDL nasty loud gap check oversold loud sentiment on macro nasty theta rocket diamond fire

  Buy

• RiskVandal

  May 2, 2024

  $CRDL wild fire clear whoa heater beastly today range hard watching clean eyes clear and today noise buzzing

  Buy

• TradeTracer

  Apr 23, 2024

  $CRDL heat level-to-level uptrend spike heavy whoa on bounce momentum mooning nimble mooning theta whispers tax

  Buy

• CashWraith

  Apr 7, 2024

  $CRDL no move gap tbh today smart on talking flows smooth whoa passed crushing eyes gains on today watching earnings

  Buy

• BullishBerserker

  Apr 2, 2024

  $CRDL keeping heat nasty wild dripping vol smooth tight level-to-level flows clean nimble run tape gap

  Buy

• DigitalDividend

  Mar 30, 2024

  $CRDL here queued bear tape supply bleeding money hurts theta candle hard ouch queued rough rough

  Sell

• BagholderPrime

  Nov 20, 2023

  $CRDL uptrend run soon-ish passed hedges trigger strong oversold vol heavy hands smart today on whispers level-to-level bid

  Buy